Company Shares of Inovio Pharmaceuticals (NASDAQ:INO) Drops by -2.57%

Inovio Pharmaceuticals (NASDAQ:INO) : During the past 4 weeks, traders have been relatively bearish on Inovio Pharmaceuticals (NASDAQ:INO), hence the stock is down -15.58% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.8% relative to the S&P 500. The 4-week change in the price of the stock is -14.22% and the stock has fallen -2.57% in the past 1 week.

The company shares have rallied 19.87% from its 1 Year high price. On Apr 28, 2016, the shares registered one year high at $11.69 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $10.33 and the 200 Day Moving Average price is recorded at $8.29.

The stock has recorded a 20-day Moving Average of 8.28% and the 50-Day Moving Average is 10.85%.


Inovio Pharmaceuticals (NASDAQ:INO): stock turned positive on Friday. Though the stock opened at $8.94, the bulls momentum made the stock top out at $9.28 level for the day. The stock recorded a low of $8.9 and closed the trading day at $9.11, in the green by 0.33%. The total traded volume for the day was 1,444,806. The stock had closed at $9.08 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Director of INOVIO PHARMACEUTICALS, INC., Collins Morton, had purchased 10,000 shares in a transaction dated on June 28, 2016. The transaction was executed at $9.13 per share with total amount equaling $91,300.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *